89075-43-4

Usage

Uses

Used in Medicinal Chemistry and Pharmaceutical Industry:
3H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)is used as a building block for the synthesis of biologically active compounds due to its unique structure and potential pharmacological properties. The presence of the imidazo[4,5-c]pyridine moiety in its structure makes it a valuable compound for drug discovery and development.
Used in Drug Discovery and Development:
3H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)is employed in drug discovery and development for its potential use in the treatment of various diseases and conditions. Its unique structure and pharmacological properties make it a promising candidate for the development of new therapeutic agents.
Used in the Synthesis of Biologically Active Compounds:
3H-Imidazo[4,5-c]pyridine, 2-(2-fluorophenyl)is used as a key intermediate in the synthesis of biologically active compounds with potential therapeutic applications. Its unique structural features and the presence of nitrogen and fluorine atoms make it a versatile building block for the development of novel pharmaceuticals.

Upstream product

• 54-96-6 3,4-diaminopyridine 
• 445-29-4 o-fluoro-benzoic acid 

Downstream Products

• 952290-96-9 C₁₉H₁₃FN₄O₂ 
• 952291-04-2 C₁₉H₂₀FN₃ 
• 952291-05-3 C₂₀H₁₆FN₃O 
• 1000787-76-7 5-[6-chloro-pyridazin-3-ylmethyl]-2-(2-fluoro-phenyl)-5H-imidazo[4,5-c]pyridine 
• 1000787-75-6 5-((6-(2,4-bis(trifluoromethyl)phenyl)pyridazin-3-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine 

Relevant academic research and scientific papers

PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, (I) wherein A1, A2, R1 and R2, have the same meaning as that defined in the claims and the description. The present inve

Crystalline pyridazine compound

A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating crystalline compound (1) are provided.

Novel pyridazine compound and use thereof

A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating compound (1) are provided.

Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: Further optimization of anti-hepatitis C virus activity

Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines represent a novel class of compounds with activity against pestiviruses and the hepatitis C virus (HCV). Several series of analogues with modifications of the substituents in positions 2 and 5 were prepared. These efforts resulted in the discovery of several compounds with potent antiviral activity of which 2-(2,3-difluorophenyl)-5-[4-(trifluoromethyl)benzyl]-5H-imidazo[4,5-c]pyridine (46) was most potent against HCV (EC50 of 0.10 μM and a selectivity index of 1080).

IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT

The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general Formula (A) wherein the substituents are described in the specification. The invention also relates to processes for the preparation and screening of compounds according to the invention having above mentioned general Formula and their use in the treatment or prophylaxis of viral infections.

VIRAL INHIBITORS

The present invention relates to a pharmaceutical composition for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine derivative having the general formula (Z): (formula). The invention als

Structure-activity relationships of arylimidazopyridine cardiotonics: Discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine

Recently several noncatecholamine, nonglycoside cardiotonic drugs have been discovered that possess both inotropic and vasodilator activities in experimental animals and man. Prototypical compounds include amrinone, sulmazole, and fenoximone. We investigated the structural requirements necessary for optimal inotropic activity in a series of molecules containing a heterocyclic ring fused to 2-phenylimidazole and discovered that 2-phenylimidazo[4,5-c]pyridines were generally 5-10-fold more potent than analogous 2-phenylimidazo[4,5-b]pyridines (e.g., sulmazole) or 8-phenylpurines. Furthermore, all imidazo[4,5-c]pyridine analogues we tested were orally active; in contrast, only one of the imidazo[4,5-b]pyridine derivatives, sulmazole, was significantly active. One of several highly active compounds in the [4,5-c] series was 50 (LY175326, 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H- imidazo[4,5-c]pyridine hydrochloride). The structure-activity relationship of this series is presented and compared to that of the imidazo[4,5-b]pyridine and purine series.